Stock Events

Stock Events

Curis 

$1.5800
79
+$0.00+0% 20:00 Today
+$0.00+0%21:35After hours

Statistics

Day High
1.65
Day Low
1.5109
52W High
39
52W Low
1.5
Volume
82,526
Avg. Volume
274,105
Mkt Cap
3.83M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-25
-16.83
-8.66
-0.49
Expected EPS
-2.666667
Actual EPS
N/A

Financials

-80.29%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
9.44MRevenue
-7.58MNet Income

Analyst Ratings

43.00Average Price Target
The highest estimate is 43.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CRIS. It's not an investment recommendation.
Tesla
15
TSLA
Amazon
15
AMZN
NVIDIA
15
NVDA
AMD
15
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Exelixis
EXEL
Mkt Cap13.4B
Exelixis focuses on the discovery, development, and commercialization of new medicines for the treatment of cancer, similar to Curis's focus on innovative therapeutics for cancer treatment.
Array Technologies
ARRY
Mkt Cap722.3M
Array BioPharma specializes in the development and commercialization of targeted small molecule drugs to treat cancer, directly competing with Curis's cancer-focused portfolio.
Incyte
INCY
Mkt Cap25.91B
Incyte Corporation operates in the same oncology sector, developing a broad portfolio of cancer treatments that directly competes with Curis's offerings.
Agios Pharmaceuticals
AGIO
Mkt Cap1.98B
Agios Pharmaceuticals focuses on cellular metabolism and rare genetic diseases, including cancer metabolism, which overlaps with Curis's research in cancer therapeutics.
Novartis
NVS
Mkt Cap301.95B
Novartis is a large pharmaceutical company with a significant oncology division, competing across a broad range of cancer treatments including areas that Curis targets.
Bristol-Myers Squibb
BMY
Mkt Cap136.88B
Bristol-Myers Squibb has a comprehensive portfolio of cancer treatments, including immunotherapies that compete with Curis's focus on innovative cancer therapeutics.

About

Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Show more...
CEO
James Dentzer
Employees
24
Country
United States
ISIN
US2312694084
WKN
000A42DTL

Listings

F
DE
CUS1.F
MU
DE
CUS1.MU
STU
DE
CUS1.STU
STU
DE
CUSA.STU

0 Comments

Share your thoughts

FAQ

What is Curis stock price today?▼
The current price of CRIS is $1.58 USD — it has increased by +0% in the past 24 hours. Watch Curis stock price performance more closely on the chart.
What is Curis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Curis stocks are traded under the ticker CRIS.
Is Curis stock price growing?▼
CRIS stock has fallen by -12.22% compared to the previous week, the month change is a -67.69% fall, over the last year Curis has showed a -95.37% decrease.
What is Curis market cap?▼
Today Curis has the market capitalization of 3.83M
When is the next Curis earnings date?▼
Curis is going to release the next earnings report on November 11, 2026.
What is Curis revenue for the last year?▼
Curis revenue for the last year amounts to 9.44M USD.
What is Curis net income for the last year?▼
CRIS net income for the last year is -7.58M USD.
How many employees does Curis have?▼
As of August 24, 2026, the company has 24 employees.
In which sector is Curis located?▼
Curis operates in the Health & Wellness sector.
When did Curis complete a stock split?▼
The last stock split for Curis was on July 06, 2026 with a ratio of 1:20.
Where is Curis headquartered?▼
Curis is headquartered in LEXINGTON, United States.